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Recommended treatment for moderate to severe asthma is the combination of an inhaled
corticosteroid and a long-acting beta2-agonist. The present study was designed to evaluate
the efficacy of a newly developed fixed combination of ciclesonide and formoterol in compar-
ison to the marketed fixed combination of fluticasone and salmeterol in patients with
moderate asthma.
This was a phase II, multi-centre, randomized, parallel-group, double-blind, double-dummy
study. After a 2-week run-in period, 160 patients with moderate asthma were randomized to
a 6-week treatment with ciclesonide/formoterol 320/9 mg bid (CIC/F) or fluticasone propio-
nate/salmeterol 250/50 mg bid (FP/S), both delivered as powder formulations.
The primary outcome FEV1 increased during treatment by 0.356 L in the CIC/F group and by
0.288 L in the FP/S group (p < 0.0001). The increases were statistically significant and clini-
cally relevant. The between-treatment analysis demonstrated non-inferiority of CIC/F to
FP/S treatment (p < 0.0001). A significant improvement from baseline in lung function,
symptom score and rescue medication use was observed in both groups at all time points.
No differences were observed between treatments in the frequency of adverse events and
overnight urinary cortisol/creatinine ratio.
The studied fixed combination of ciclesonide/formoterol is not inferior to the marketed
fixed combination of fluticasone/salmeterol in terms of efficacy and tolerability.
ª 2011 Elsevier Ltd. All rights reserved.Introduction
Asthma is a chronic disease of the airways, causing recur-
rent episodes of symptoms, variable airflow limitation, and
increased airway responsiveness. International guidelines31 17 5785; fax: þ49 6131 17 56
unimedizin-mainz.de (S. Korn), R
1 Elsevier Ltd. All rights reservedrecommend the combination of a long-acting beta2-agonist
(LABA) with low-to-medium dose inhaled corticosteroids
(ICS) if asthma is not fully controlled by ICS alone, as first
choice treatment in moderate asthma.1e5 Several clinical
trials have shown that the addition of a LABA to ICS is more61.
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58 S. Korn, R. Buhlbeneficial than increasing the dose of ICS alone in terms of
symptom control and pulmonary function.6e10 The intro-
duction of LABA to the treatment of asthma has changed
the way in which b2-agonists are used from simple rescue
agents to medication that provides long lasting bronchodi-
lation and thus reduces the need for rescue treatment.
Landmark studies demonstrated that combined therapy
with ICS and LABA provides better asthma control than high
doses of ICS alone.1,11 Treatment with an ICS/LABA
combination in a single inhaler, with the same efficacy and
safety profile as the two drugs given separately, may also
produce a better adherence to anti-inflammatory
treatment.12e19 To date, several fixed ICS/LABA combina-
tion inhalers are widely used, offering improvements in
control in patients with persistent asthma compared with
ICS therapy alone as well as with free combinations of the
same drugs.2e4,20,21 Consequently, a combination treat-
ment of the inhaled glucocorticosteroid ciclesonide and the
long-acting beta2-agonist formoterol fumarate (abbrevi-
ated as formoterol) was developed for the treatment of
persistent asthma. Ciclesonide is an effective and safe drug
for the treatment of asthma. In a number of studies cicle-
sonide was shown to be non-inferior to fluticasone propio-
nate (FP) and budesonide (Bud) with regard to lung function
variables, improvement of asthma symptoms, and reduc-
tion of the use of rescue medication.22e25 Formoterol
belongs to a class of b2-agonists that have a fast onset and
a long duration of action and are able to maintain bron-
chodilation for at least 12 h. As formoterol is widely used
for long-term maintenance treatment of asthma and for the
prevention of bronchospasm, a substantial amount of
information is available on the substance.26
In this exploratory study the efficacy of the fixed
combinations of ciclesonide and formoterol and of FP and
salmeterol xinafoate (abbreviated as salmeterol) was
assessed in patients with moderate asthma.
Methods
This was a 10-week, multi-centre, randomized, parallel-
group, double-blind, double-dummy study. The study
(EudraCT number 2004-002983-80 registered at https://
www.clinicaltrialsregister.eu/) was approved by the Insti-
tutional Review Board or Independent Ethics Committee of
each participating centre and was conducted in accordance
with the ethical principles embodied in the Declaration of
Helsinki and local applicable laws and regulations. All
patients provided written informed consent prior to taking
part in the study.
Selection of the study population
The study was carried out in 11 outpatient respiratory
clinics in Germany and Austria. The study enrolled male and
female patients aged 12e75 years with a history of asthma
for at least 6 months, with an FEV1 >60% to <80% of pre-
dicted, when short-acting rescue medication was withheld
for at least 6 h and patients who were in good health, with
the exception of asthma. All eligible patients had to be pre-
treated either with a constant dose of 500 mg fluticasone
(or equivalent) per day only, or with a constant dose of250 mg fluticasone (or equivalent) per day in combination
with an inhaled LABA in a fixed or free combination, or
sustained-release theophylline, or a leukotriene antago-
nist, or a lipoxygenase inhibitor, or inhaled anticholiner-
gics, or an oral b-agonist, or inhaled disodium
cromoglycate, or inhaled nedocromil during at least four
weeks prior to entry into the study. After the run-in period
(two weeks) patients were randomized to study drug if they
demonstrated reversibility by DFEV1 15% after inhalation
of 200e400 mg salbutamol or, if during run-in reversibility
was not achieved, diurnal PEF variation 15% during at
least three days within the last seven days of the run-in
period. Additionally, asthma symptoms had to occur more
than once a week, but less than once a day.
Patients with COPD and/or other relevant lung diseases
causing alternating impairment in pulmonary function,
current smokers or ex-smokers for 6 months or a smoking
history of 10 cigarette pack years and patients using
systemic glucocorticosteroids within 2 months prior to entry
into the study, or more than 3 courses during the last 6
months were excluded.Study treatments and design
Study drugs were a newly developed fixed combination of
320 mg ciclesonide and 9 mg formoterol and the marketed
salmeterol/fluticasone fixed combination (50 mg/250 mg),
both formulated as a powder. The appropriate dosing of the
new CIC/F compound was estimated based on phase I
safety data and the fine particle fraction of the new powder
formulation which is approximately 50% smaller than that
of the ciclesonide hydrofluoroalkane metered-dose inhaler
(HFA MDI).
The study protocol comprised a screening visit, a 14-day
run-in period (patients continued their previous asthma
medication), a 6-week treatment period, and a follow-up
period (Fig. 1). Patients were allowed to use salbutamol as
rescue medication throughout the study. At visit 2 eligible
patients were randomized to treatment with ciclesonide/
formoterol 320/9 mg bid (total daily dose of ciclesonide
640 mg, formoterol 18 mg (CIC/F)) or fluticasone propio-
nate/salmeterol 250/50 mg bid (total daily dose of flutica-
sone 500 mg, salmeterol 100 mg (FP/S)) (ratio 1:1).
Randomization was in balance-block design by investiga-
tional centre. Patients received the study medication using
two different DPIs: one Ultrahaler and one Diskus. Due
to the double-dummy technique and the code labelling,
neither the patient nor the investigator or anyone else
involved in the study knew throughout the study whether
CIC640/F18 or FP500/S100 was administered during the
treatment period.
Lung function (FEV1: forced expiratory volume in 1 s,
FVC: forced vital capacity, FEF25-75%: mean forced expi-
ratory flow between 25% and 75% of vital capacity) was
measured at visits 1, 2 (baseline), 3, and 4. Throughout the
study patients recorded their morning and evening PEF
(peak expiratory flow), use of rescue medication, and
asthma-related symptoms in an electronic diary. Adverse
events (AEs) and use of concomitant medication were
documented by the investigator throughout the study. At
study visits 1, 3, 4, and a follow-up visit (if applicable)
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free cortisol (24-h) was determined at visits 1 and 4.
Physical examination (including vital signs) and assessment
of skin bruising were performed at every study visit. ECG
was recorded at visits 1, 3, and 4.
Protocol outcome measures
The primary efficacy variable was the difference in FEV1 (L)
between the last available valid visit (up to visit 4) and visit
2. The co-primary efficacy variable was the percentage of
days without asthma symptoms and use of rescue medica-
tion (%) (diary, last four weeks during treatment compared
with the two run-in weeks).
At each study visit, FEV1, FVC, and FEF25-75% (tripli-
cate) were recorded. Individual spirograms were checked
by the investigator for acceptability and reproducibility.27
Before pulmonary function tests (PFT) rescue medication
had to be withheld for at least 6 h. PFT was performed in
accordance with standard procedure,28 at each visit before
the intake of the morning dosage of baseline or study
medication, meaning that the morning dose of study drug
was taken onsite after PFT under the investigator’s super-
vision and proper inhaler technique was checked.
To assess reversibility the patient inhaled 200 mg salbu-
tamol after initial lung PFT. Triplicate lung function
measurements were repeated after 15 min. In case ofEnrolle
n=223
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n = 16
Allocated to CIC/F
n = 81
Treatment discontinuation
n = 5
Completed study
n = 76
Individual ICS pre-treatment
4 weeks prior to visit 0 at a constant daily dose of
up to 500 µg fluticasone or 250 µg fluticasone in
combination with a non-steroidal controller drug
Continuatio
individual trea
Run-in per
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1Visit
a
b
Figure 1 a) Study flow chainsufficient response (DFEV1 < 15% of initial), another dose
of 200 mg salbutamol was inhaled and further FEV1 readings
obtained 15 min thereafter. It was also acceptable to
administer 400 mg salbutamol in one dose after initial PFT
and perform just one set of triplicate PFT after 15 min.
Patients recorded PEF using an electronic PEF metre
(AM2þ, VIASYS) daily in the morning immediately after
getting up and in the evening before going to bed. Readings
were done more than 6 h after use of rescue medication
and before inhalation of baseline and study medication. At
each home measurement, three readings were obtained
and recorded in the diary; the highest value was used for
evaluation. Diurnal PEF fluctuation was calculated by the
electronic PEF metre. The highest morning and the highest
evening value from the same day were selected.
Additional study parameters included nighttime and
daytime asthma symptoms and the daily use of rescue
medication (salbutamol), assessed on a daily basis by the
patient in the diary of the electronic PEF metre. Asthma
exacerbation or lack of efficacy was defined as increasing
asthma symptoms or a distinct drop in lung function (e.g.
decrease in morning PEF on two consecutive days by more
than 30% below the best value recorded during the baseline
period) requiring treatment with oral glucocorticosteroids.
If an asthma exacerbation occurred during the study the
patient was withdrawn from further participation and
treated according to individual needs.d
Withdrawn prior
to randomization
n = 63
zed
0
Allocated to FP/S
n = 79
Treatment discontinuation
n = 4
Completed study
n = 75
n of 
tment
CIC640 / F18 µg daily
FP500 / S100 µg daily
iod Treatment period
6 weeks
2 3 4
Follow-up period
up to 30 days
rt. b) Patient flow chart.
60 S. Korn, R. BuhlSafety assessments included recording of adverse events
(AEs) and serious adverse events (SAEs), collection of clin-
ical laboratory data for haematology and blood chemistry,
monitoring of vital signs, electrocardiogram (ECG), and
oropharyngeal examinations. The intensity of AEs was
assessed as being mild, moderate or severe. Suspected oral
candidiasis had to be confirmed by a swab culture.
A list of secondary variables is available as part of the
online repository.Statistics
Spirometric lung function variables as well as morning and
evening PEF from diary were analyzed with an ANCOVA
(analysis of covariance). The dependent variable was the
difference of the values of visits after randomization to the
value at visit 2. Besides the treatment, the following
factors and covariates (all fixed) were included in the
model: value at visit 2, age, sex, and country (Germany and
Austria), more so as the 2 populations differ in median age.
However, baseline values of FEV1 (absolute and percent
predicted) match very well in both groups irrespective of
age. To overcome the problem that age (or other cova-
riates) may have a significant impact on the outcome of the
trial the ANCOVA model included age as covariate and
treatment least square means are presented.
No interaction term was included in this model, which
was used to test both within- and between-treatment
differences. With regard to the primary variable FEV1,
the comparison between treatments was based on the
difference between visit 4 or the last available measure-
ment during treatment (PP (per protocol) analysis) and the
baseline value at randomization (visit 2), while for the co-
primary variable percent days without asthma symptoms
and use of rescue medication it was based on the difference
between Ilast (interval of the last four treatment weeks,
mITT (modified intention-to-treat) analysis) and Irun-in (run-
in interval, two weeks before visit 2). The mITT corresponds
to ITT analysis but conducted “as treated” (not “as
randomized”). The non-inferiority acceptance limit for
FEV1 was 0.200 L. An additional repeated measurement
model was analyzed to investigate the robustness of the
results of the endpoint analysis.
Diurnal PEF fluctuation, asthma symptom scores, use of
rescue medication, and asthma control variables were
analyzed non-parametrically. Within-group differences
were analyzed with Pratt’s modification of Wilcoxon’s
signed rank test; between-treatment comparisons were
analyzed with the ManneWhitney U test. The difference
between treatments with respect to the frequency of local
oropharyngeal AEs was analyzed by means of Fisher’s exact
test. Between-treatment differences of urine free cortisol
variables were analyzed with the nonparametric van Elte-
ren test, stratified by centre pool. Descriptive statistics are
given for AEs, laboratory variables, and vital signs. A sample
size of nZ 75 randomized patients per group was primarily
chosen on grounds of feasibility, resulting in ca. 60 patients
per group in the PP analysis. This gave a power of 77% to
demonstrate non-inferiority with regard to FEV1 for
a common standard deviation of 400 mL and no between-
treatment difference at the one-sided 2.5% levelconfirmed by nQuery, version 7. All analyses are PP,
confirmed by mITT.
Results
One hundred and sixty patients with moderate asthma were
randomized and included in the full analysis set
(NZ 81 CIC/F and NZ 79 FP/S). Baseline data (Table 1) of
the two groups were comparable though patients in the
CIC/F group tended to be younger than those in the FP/S
group (median of 44 and 51 years, respectively).
Efficacy results
Lung function
The primary outcome parameter FEV1 increased signifi-
cantly and clinically relevant by 0.356 L in the CIC/F group
and by 0.288 L in the FP/S group during the treatment
period (Fig. 2, Table 2). The between-treatment analysis
demonstrated non-inferiority of CIC/F to FP/S treatment
(non-inferiority margin 0.200 L). As non-inferiority of CIC/
F to FP/S was shown for the primary variable, the co-
primary variable patient perceived asthma control (based
on symptoms and use of rescue medication) was tested
subsequently for difference between CIC/F and FP/S with
a confirmatory intention. Improvements in asthma control
were observed in both treatment groups (Table 3), with no
statistically significant difference between treatments. For
FVC a statistically significant increase occurred in both
treatment groups (Table 2), with non-inferiority of CIC/F to
FP/S also demonstrated for FVC (non-inferiority margin
0.200 L). Repeated measurement analysis of FEV1, FVC,
and FEF25e75% confirmed the results of the endpoint
analyses.
Morning and evening PEF from diary increased statisti-
cally significantly in both treatment groups (CIC/F morning/
evening change in PEF compared to baseline (LSMean  SE)
20.7  7.8, p Z 0.0088/19.5  7.4, p Z 0.0097; FP/S
19.5  7.9, p Z 0.0146/15.6  7.5, p Z 0.0399; Fig. 2b).
Between-treatment comparisons demonstrated non-inferi-
ority of CIC/F to FP/S for both variables (non-inferiority
margin 25 L/min). PEF variability decreased statistically
significantly during treatment with CIC/F only, while there
was no statistically significant difference between
treatments.
Asthma symptoms
Asthma symptom scores (total, daytime, and nighttime)
decreased statistically significantly with both treatments
(CIC/F decrease sum (Hodges-Lehmann point estimate)
0.43, p < 0.0001; FP/S 0.42, p < 0.0001), with no statis-
tically significant difference between the two treatments.
Comparable improvements were seen for the use of rescue
medication and the percentage of asthma symptom-, rescue
medication-, and nocturnal awakening-free days.
Safety results
Adverse events
During the treatment period 37 (45.7%) patients in the CIC/
F group experienced 60 AEs and 29 (36.7%) patients in the
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reported AEs belonged to the system organ class infections.
Within this class, oral candidiasis was the most common AE,
reported by six patients in each treatment group. The
majority of AEs was moderate in intensity in both treat-
ment groups. No severe AEs were reported. The number of
AEs assessed by the investigator as likely related to study
medication was comparable in both treatment groups
(14.8% of patients in the CIC/F group and 12.7% in the FP/S
group). Only one patient in the CIC/F group experienced
AEs that were assessed as definitely related by the inves-
tigator (asthenia and tremor). Two patients in the CIC/F
group experienced treatment-emergent AEs related to
cardiac disorders. The events were non-serious, mild
(cardiovascular disorder, AE verbatim: circulatory distur-
bance) and moderate (atrial fibrillation and tachycardia) in
intensity and both patients recovered without sequelae.
The investigator assessed the tachycardia and the atrial
fibrillation as likely related to the intake of study medi-
cation; the cardiovascular disorder was assessed as
unrelated.
No death occurred during the study and only one SAE
(‘loose body in joint’) was reported in the CIC/F group
(patient was hospitalized for this SAE). The patient did
not discontinue the study and the SAE was assessed as
unrelated to study medication by the investigator. The
patient recovered from the SAE without sequelae five
days after onset. Three patients in the CIC/F group andTable 1 Demographic and other baseline characteristics.
Demographic characteristics FAS
CIC640/F18
(N Z 81)
Age (years) Median (range) 44 (12, 71)
Weight (kg) Mean  SD 79  16
Height (cm) Mean  SD 171  10
Sex (n (%)) Male 39 (48.1)
Pretreatment
at visit 0 (n (%))
ICS only 17 (21.0)
ICS and LABA 63 (77.8)
ICS and other 1 (1.2)
Smoking status (n (%)) Non-smokers 53 (65.4)
Ex-Smokers 28 (34.6)
Pack-years Mean  SD 5.8  2.3
FEV1 at visit 1 (L) Mean  SD 2.304  0.540
FEV1 (% of predicted) Mean  SD 70.2  5.5
FEV1 at visit 2 (L) Mean  SD 2.376  0.535
FEV1 at visit 2
(% of predicted)
Mean  SD 72.5  5.3
Reversibility
(% increase)
Mean  SD 23.2  7.2
Symptome score
sum at W0
Median (range) 0.7 (0.0, 2.9)
Use of rescue
medication at W0
Median (range) 1.0 (0.0, 6.4)
Numbers and percentages are based on the number of patients with
CIC640/F18 Z ciclesonide/formoterol 320/9 mg twice daily, FP500/S
ICSZ inhaled corticosteroid, LABAZ long-acting b2-agonist, visit 1Z
visit 2, NA Z not applicable, SD Z standard deviation.two patients in the FP/S group discontinued the study
due to an AE. None of these AEs were serious or severe in
intensity.
Clinical laboratory
There were no clinically relevant changes in laboratory
values over time in any of the treatment groups. Nine
patients in the CIC/F and seven patients in the FP/S group
reported AEs associated with abnormal laboratory values.
They were all mild or moderate in intensity and assessed by
the investigator as unrelated or unlikely related, apart from
one incidence of increased blood glucose in the FP/S group,
which was likely related to study medication.
Urine free cortisol adjusted for creatinine remained
unchanged during treatment with CIC/F, while it decreased
statistically significantly in the FP/S group (p Z 0.0277,
restricted SAF, confirmed by the full analysis set). Between
treatments no statistically significant difference was
observed.
Physical examination and vital signs
Physical examination, blood pressure, and heart ratio
measured at site visits during the study period did not
reveal any influence of the two different treatments. Due
to the small number of skin bruises, analysis was omitted.
Only one clinically relevant finding was recorded on ECG
data: one patient had intermittent atrial fibrillation at visit
4, which was reported as an AE (see above).VCS
FP500/S100
(N Z 79)
CIC640/F18
(N Z 67)
FP500/S100
(N Z 68)
51 (12, 75) 43 (12, 71) 51 (12, 75)
78  17 79  16 78  17
169  9 171  10 169  9
37 (46.8) 30 (44.8) 33 (48.5)
12 (21.5) 14 (20.9) 15 (22.1)
61 (77.2) 53 (79.1) 53 (77.9)
1 (1.3) NA NA
58 (73.4) 44 (65.7) 49 (72.1)
21 (26.6) 23 (34.3) 19 (27.9)
5.1  2.4 5.8  2.3 4.9  2.4
2.226  0.590 2.277  0.516 2.218  0.599
71.1  5.5 70.3  5.5 70.7  5.6
2.269  0.597 2.327  0.523 2.265  0.580
72.6  5.5 71.8  5.0 72.4  5.2
20.7  8.3 22.7  7.0 19.5  6.9
0.7 (0.0, 2.8) 0.7 (0.0, 2.7) 0.7 (0.1, 2.8)
1.0 (0.0, 6.6) 1.0 (0.0, 5.7) 1.0 (0.0, 6.6)
data available. FAS Z full analysis set, VCS Z valid cases set,
100 Z fluticasone propionate/salmeterol 250/50 mg twice daily,
baseline visit, visit 2Z randomization visit, W0Z week before
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The present clinical trial demonstrated comparable effi-
cacy of the two fixed combinations CIC/F and FP/S in
patients with moderate asthma, pre-treated with ICS alone
or in combination with another asthma drug in a well
controlled study design. The two treatment groups were
matched in terms of asthma severity and baseline values of
all outcome measures evaluated.
The populations in both treatment groups had a real
potential to improve from baseline to endpoint, as2
2,1
2,2
2,3
2,4
2,5
2,6
2,7
2,8
21
FEV1 (L)
330
350
370
390
410
0 1 2
Morning PEF (L/min)
a
b
Figure 2 a) Time course of FEV1 (L) (PP analysis), Mean and SEM
Mean and SEM for the time course, PP.demonstrated by the significant increases in lung function
during the course of the study, showing real equivalence
between the two study treatments. In addition, equiva-
lence was not due to lack of efficacy for both treatments.29
The increases in the primary efficacy variable between
baseline and end of study were both statistically significant
and clinically relevant in both groups, confirming that the
study had the power to detect potential differences
between groups. This is true although the minimum dose
required to achieve asthma control was not established in
the study. The results of the other pulmonary function43
Visit
CIC/F
FP/S
Week
3 4 6
CIC/F
FP/S
for the time course, PP. b) Time course of morning peak flow,
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the site visits, showed comparable increases in the two
groups and are in line with previous study results.20,21,30e32
In addition, comparable improvements in the two groups
were observed in the assessment of clinical symptoms and
in the use of rescue salbutamol, which significantly
decreased from baseline to end of study with no difference
between groups. The two combination treatments showed
similar tolerability profiles.
Combination therapies are routinely used as part of
regimens where the maintenance dose of ICS/LABA is
titrated up to achieve stable asthma control, and, when
adequate control is maintained, titrated down with the aimTable 2 Change in FEV1 (L), FVC (L), FEF25-75% (L/s) from T0: w
(PP, mITT)
WITHIN
N Visit 2
Mean % pred. LSMean
FEV1
PP analysis
CIC640/F18 61 2.298 71.9 2.293
FP500/S100 62 2.289 72.3 2.293
mITT analysis
CIC640/F18 81 2.376 72.5 2.323
FP500/S100 79 2.269 72.6 2.323
FVC
PP analysis
CIC640/F18 61 3.225 84.8 3.195
FP500/S100 62 3.166 83.1 3.195
mITT analysis
CIC640/F18 81 3.367 85.9 3.283
FP500/S100 79 3.197 85.1 3.283
FEF25e75%
PP analysis
CIC640/F18 58 1.633 43.6 1.645
FP500/S100 61 1.656 45.0 1.645
mITT analysis
CIC640/F18 78 1.672 44.0 1.642
FP500/S100 78 1.612 44.1 1.642
BETWEEN
Test Ref n Test Difference Te
n Ref LSMea
FEV1
PP analysis CIC640/F18 FP500/S100 61 62 0.06
mITT analysis CIC640/F18 FP500/S100 81 79 0.01
FVC
PP analysis CIC640/F18 FP500/S100 61 62 0.17
mITT analysis CIC640/F18 FP500/S100 81 79 0.11
FEF25e75%
PP analysis CIC640/F18 FP500/S100 58 61 0.08
mITT analysis CIC640/F18 FP500/S100 78 78 0.14
CIZ confidence interval, CIC640/F18Z ciclesonide/formoterol 320/9
250/50 mg twice daily, LS Z least squares, SE Z standard error of th
a Two-sided p-value for within-treatment differences, significance l
b One-sided p-value for non-inferiority, significance level 2.5%, non
c One-sided p-value for superiority, significance level 2.5%.of minimizing the overall drug load whilst maintaining
stable control.19,33 Both patient compliance and long-term
pulmonary function benefit from single inhaler treatment
with LABA and ICS.10,34,35 This treatment regimen allows
the patient to perceive the relief of symptoms provided by
the LABA, thus enhancing compliance, while receiving
a maintenance dose of the ICS that acts on the chronic
airways inflammation, hence improving disease control.
Moreover, the use of fixed combinations reduces the direct
and indirect treatment costs compared with the adminis-
tration of the same drugs given by separate inhalers.36
Taking into consideration the evidence-based advantages
offered by the combined administration of LABA/ICS, theithin- and between-treatment differences, endpoint analysis
Visit 4 Visit 4  visit 2
LSMean LSMean  SE 95% CI p-valuea
2.650 0.356  0.045 0.267, 0.446 <0.0001
2.582 0.288  0.044 0.200, 0.376 <0.0001
2.643 0.320  0.042 0.237, 0.402 <0.0001
2.629 0.306  0.042 0.223, 0.389 <0.0001
3.656 0.460  0.060 0.341, 0.580 <0.0001
3.479 0.284  0.059 0.166, 0.401 <0.0001
3.681 0.398  0.054 0.292, 0.505 <0.0001
3.562 0.279  0.054 0.172, 0.387 <0.0001
1.989 0.344  0.071 0.204, 0.484 <0.0001
2.072 0.427  0.069 0.291, 0.563 <0.0001
1.941 0.299  0.060 0.179, 0.418 <0.0001
2.082 0.440  0.060 0.321, 0.560 <0.0001
st  Ref for visit 4  visit 2
nSE 95% CI p-value non-inf.b p-value sup.c
8  0.063 0.057, 0.193 <0.0001 0.1412
3  0.059 0.103, 0.130 0.0002 0.4109
7  0.084 0.010, 0.343 <0.0001 0.0190
9  0.076 0.032, 0.270 <0.0001 0.0602
3  0.098 0.277, 0.111 NA 0.8011
2  0.085 0.310, 0.026 NA 0.9510
mg twice daily, FP500/S100Z fluticasone propionate/salmeterol
e LSMean
evel 5%.
-inferiority margin Z 200 mL.
64 S. Korn, R. Buhlstudied ciclesonide/formoterol combination is a valid
alternative in the treatment of asthma. Moreover, in view
of the fact that ciclesonide is an established ICS used
worldwide, the availability of a ciclesonide/formoterol
combination may also allow patients not adequately
controlled with ICS alone to increase treatment intensity
using a familiar molecule in the same inhaler. In addition,
due to its pharmacodynamic properties formoterol, a full
b2-agonist is thought to be more efficacious than the partial
b2-agonist salmeterol, in particular during periods of
increased inflammation or challenge.12 Although not tested
in the present trial, the specific properties of formoterol,
among them its rapid onset of action and the clear dose-
response-relationship, offer the potential of using cicleso-
nide/formoterol as maintenance and reliever therapy,
which simplifies treatment for both patients and clinicians
by delivering effective asthma control using a single
inhaler. This enables patients to respond at the first sign of
symptoms by taking additional as-needed inhalations of
ciclesonide/formoterol to achieve rapid und sustained
relief of symptoms, with every dose being accompanied by
additional anti-inflammatory therapy.37 Another attractive
aspect of the fixed ciclesonide/formoterol combination is
the 24 h duration of action of both components, offering
patients the flexibility to use the drug on a once daily basis
either in the morning or in the evening.22,38
LABAs are the first choice add-on treatments for patients
poorly controlled on low-dose ICS,with a SABA to be provided
as reliever medication.5 However, overuse of SABAs or for-
moterol, a rapid- and long-acting b-agonist, as reliever
medication is a well known problem for asthma patients,39,40
and it has long been established that increased reliever use,
without sufficient anti-inflammatory therapy, increases the
risk of asthma morbidity and mortality.41,42 In fact, overuseTable 3 Percent days without symptoms and use rescue medica
comparison (mITT, PP).
WITHIN
N Irun-in Median Ilast/end Median
PP analysis
CIC640/F18 64 41.7 73.0
FP500/S100 68 38.5 74.0
mITT analysis
CIC640/F18 81 41.7 75.0
FP500/S100 79 30.8 66.7
BETWEEN
Test Ref n Test n Ref Diffe
HL p
PP analysis CIC640/F18 FP500/S100 64 68 4.0
mITT analysis CIC640/F18 FP500/S100 81 79 4.7
CIZ confidence interval, CIC640/F18Z ciclesonide/formoterol 320/9
250/50 mg twice daily, HL Z Hodges-Lehmann, Irun-in Z run-in inte
treatment weeks (mITT/PP analysis).
a Two-sided p-value for within-treatment differences, significance l
b Two-sided p-value for between-treatment differences, significanc
c One-sided p-value for superiority, significance level 2.5%.of SABA or LABA without concomitant ICS should be avoided
as it could lead to under-treatment of the inflammatory
process, masking inflammation, and so leading to more
severe and potentially life-threatening exacerbations.41
Recently the safety of LABA treatment in patients with
asthmahas beenquestioned.43,44 TheUnited States Food and
Drugs Administration (FDA) mandated label changes
impacting LABA use in the USA,45 and requested new studies
of their efficacy and safety. The FDA has determined single-
ingredient LABAs should only be used in combination with an
asthma controller medication and should only be used long-
term in patients whose asthma cannot be adequately
controlled on asthma controller medications.46 Ciclesonide/
formoterol treatment ensures anti-inflammatory therapy is
delivered in combination with a LABA and thus appears as
a regimen that may also contribute to the safety of combi-
nation therapy. More so, using a single ICS/LABA inhaler both
for maintenance and reliever therapy is the only therapeutic
strategy in asthma which definitely prevents SABA or LABA
monotherapy.19,35
The present study has several limitations. Firstly, daily
doses of 640 mg ciclesonide, and 500 mg fluticasone were
tested. Based on the most recent GINA guidelines,5 the
ciclesonide dose seems to be more potent than the fluti-
casone dose. However, the GINA equivalence table is solely
based on studies with the commercially available cicleso-
nide preparation, a solution delivered by a HFA MDI. HFA
MDIs generate a greater mass of fine particles and yield
a finer spray of particles, resulting in a better pulmonary
deposition and greater percentage of the inhaled dose
being deposited in the small airways.22 In contrast, in the
present study a newly developed powder formulation of
ciclesonide/formoterol was used. Appropriate dosing of this
new compound was estimated on the basis of phase I safetytion n: within- and between-treatment differences, per/post
Ilast/end  Irun-in
HL point estimate 95% CI p-valuea
27.0 20.2, 33.9 <0.0001
22.8 15.9, 29.8 <0.0001
25.3 19.2, 31.4 <0.0001
20.5 14.5, 27.5 <0.0001
rence Test  Ref for Ilast/end  Irun-in
oint estimate 95% CI p-value 2-sidedb p-value sup.c
6.0, 13.8 0.4163 0.2082
4.6, 13.4 0.3002 0.1501
mg twice daily, FP500/S100Z fluticasone propionate/salmeterol
rval (two weeks before I0), Ilast/end Z interval of the last four
evel 5%.
e level 5%.
Fixed combination of ciclesonide and formoterol 65data and of the fine particle fraction of the powder
formulation which is smaller than that of the ciclesonide
HFA MDI. The results of the trial support the assumption
that the doses of the two corticosteroids and of the two b-
agonists are more or less equivalent. However, it cannot be
ruled out that the minor differences in effects of the two
compounds were partly due to non-equivalent corticoste-
roid doses. This is true even though local and systemic
tolerability were similar. Secondly, CIC/F patients were
younger, and the median duration of asthma was longer in
the FP/S patients, unusually for a randomized trial. It
cannot be excluded that this disparity had an influence on
the outcome of the trial. Finally, a treatment period of
some six weeks is definitely too short to address patient-
relevant endpoints such as exacerbations, and the small
number of patients together with the short duration of the
trial makes it impossible to detect rare adverse events. This
is true despite the fact that both ciclesonide and for-
moterol are widely used as single agents for many years,
and that it is highly unlikely that the same drugs given as
a fixed combination will behave differently from a free
combination of the same drugs. Further studies will have to
address these issues as well as the question if the results
seen in this study can be generalized to patients with other
degrees of severity. Similarly, no difference was found in
the rates of asthma exacerbations. However, it was not
possible to treat exacerbation rate as a primary endpoint in
the present study, since exposure time was limited and
more patients are needed in order to detect potential
differences between treatments.
Conclusion
The present study is the first to evaluate the efficacy and
safety of a DPI containing the combination ciclesonide/
formoterol together with a standard combination of fluti-
casone/salmeterol in patients with moderate asthma. Non-
inferiority of CIC/F to FP/S treatment was demonstrated
regarding the primary variable FEV1 and no difference
between treatments was observed for the co-primary
variable patient perceived asthma control (based on
symptoms and use of rescue medication). Both treatments
were effective in improving lung function and all secondary
efficacy variables in asthma. The 6-week treatment with
CIC/F did not indicate any new safety risks of both
components in this patient group. The new ciclesonide/
formoterol combination is a valid alternative for the
treatment of asthma patients not controlled on an ICS
alone. It has an efficacy and safety profile comparable to
the fixed budesonide/formoterol and beclomethasone/
formoterol combinations.20,21,30e32,47e49
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